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Abstract
Unrelated donor cord blood (CB) is one of the three sources of hematopoietic stem cell
transplantation (HSCT) that are capable of curing ~80–160 standard hematologic and
certain  non-hematologic  indications.  Despite  its  many  advantages,  the  principal
drawback for CB in HSCT is its limited cell dose. Our group has focused on developing
minimally manipulated technologies and strategies to maximize stem, progenitor, and
nucleated cell doses to overcome this limitation. The term “MaxCell” is used in this
chapter to denote two proprietary CB volume reduction processing technologies that
yield virtually 100% recovery of all cell lineages in the manufactured CB products,
including what the authors designate as “second generation” (2nd Gen) or plasma
depletion/reduction (PDR) and “third generation” (3rd Gen) MaxCB or MaxCord CB
processing technologies. In our proposed nomenclature system, the traditional red cell
reduction (RCR) processing techniques are designated as “first generation” methods.
The properties of various popular 1st Gen techniques are compared to the MaxCell CB
processing technologies. Parallel processing with the traditional hetastarch (HES) RCR
technique and the patented MaxCell CB processing technology were used to compare
recovery of the various stem, progenitor, nucleated, and red cell lineages. MaxCell
processing technology achieved virtually 100% recovery of all stem, progenitor, and
nucleated cells tested after processing, with high cell viability upon thawing. The higher
cell recovery produced MaxCell inventory with higher average stem, progenitor and
nucleated cell doses, allowing patients to receive CB products with higher cell doses.
Clinical outcome of HSCT using MaxCell CB products was compared to the outcome
of  HSCT with  RCR CB products  published in  the  literature  from transplant  data
registries or CB banks. To allow for more rigorous comparisons, two matched-pair
analysis (MP) were performed using a logistic regression model to find pairs of pediatric
patients with hematologic malignancies and thalassemia transplanted with RCR CB or
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MaxCell CB, and patients receiving MaxCell CB showed superior engraftment, survival,
and transplant-related mortality, confirming pre-match observations.
In addition, the three main post-thaw manipulation methods are reviewed. Compar-
ison data for some of the thaw methods are presented, and matched-pair analysis was
used to confirm the superiority of direct infusion thaw method over post-thaw wash
for MaxCell CB products.
Keywords: cord blood banking, cord blood processing, MaxCell cord blood process-
ing, MaxCB cord blood processing, stem cell processing, cord blood thawing, cord
blood cryopreservation, cord blood transplantation, 2nd and 3rd generation cord
blood technologies
1. Introduction
Today, hematopoietic stem cell transplantation (HSCT) can be performed using stem cells
derived from three sources: bone marrow (BM), peripheral blood (PB), and umbilical cord
blood (CB) from autologous, related allogeneic, or unrelated allogeneic donors. Autologous
HSCT is not indicated for most indications, and only about one-third of patients in need of
HSCT have a suitable related donor. Although there are currently tens of millions of adult
volunteer donors registered worldwide, about 60% of patients will not find a suitably HLA-
matched unrelated adult donor, and thus cannot access HSCT [1]. For minority patients, the
probability of finding an HLA-matched unrelated adult donor is further reduced. Since the
search process for an adult donor often takes several months, a significant proportion of
patients will become higher risk or ineligible for HSCT or even die while waiting for the donor
search [2]. In contrast, without the possibility of last minute donor refusal, CB products are
available upon request and can be shipped to any transplant center in the world immediately.
Importantly,  cord  blood transplantation  (CBT)  is  associated  with  a  lower  incidence  and
severity of graft-versus-host disease (GvHD), and a partial HLA match between the donor
and recipient is tolerable [3], making it an ideal donor source for minority patients without
large adult donor registries.
Compared with historical controls of BM or PB HSCT, CBT has shown favorable clinical
outcome despite significantly worse HLA match [3]. In the pediatric setting, CBT can be now
considered established practice. For adults, CBT adoption has been slower because of cell dose
limitation. Many strategies focused on overcoming this limitation are being developed,
including double CBT, the utilization of two CB unit grafts [4–6], the combination of an
unrelated CB graft with haplo-identical donor stem cells [7], and foregoing the post-thaw wash
with direct infusion or reconstitution/dilution, which have shown promising results [8, 9].
Engraftment and survival appear to be at least equivalent to or may even be superior to
historical data using post-thaw wash for CB products versus when CB was not washed. One
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area which our group has focused on has been the optimization of the entire CB banking
process, and in particular, the CB processing and thaw manipulations.
Almost all the published literature on CB processing has shown significant cell losses with
various volume-reduction red cell reduction (RCR) processing techniques (referred to in this
chapter as first generation or 1st Gen), such as the hydroxyethyl starch (hetastarch or HES)
sedimentation technique, Optipress II, AXP-Express, PrepaCyte, Sepax etc.,…, with the range
of loss generally around 25% for total nucleated cells (TNC) and with commensurate or higher
CD34+ progenitor and colony-forming unit (CFU) loss [10–17]. As this is one of the areas that
CB banks (CBBs) can have an impact, Chow has developed two novel MaxCell CB processing
technologies to improve cell doses of CB products—plasma depletion/reduction processing
without the reduction of red blood cells (RBC) or second generation (2nd Gen) [18] and the
MaxCord or MaxCB third generation (3rd Gen) technology which combines the advantages of
1st Gen and 2nd Gen, without any of the associated disadvantages. While the processing
methods and cryopreserved products are distinctly different, the cellular composition of the
final infused product is identical between the two MaxCell technologies in the preferred
embodiment of 3rd Gen.
Another area which has significant impact on CB potency and clinical outcome is the thaw and
post-thaw manipulations of CB products. Transplant centers which do not follow CBB’s
prescribed and validated procedure for thawing risk decreased viability of the CB product for
their patients, delayed engraftment, graft failure, transplant-related mortality, and the
potential for severe adverse events (SAE) in rare cases due to thaw and Dimethyl sulfoxide
(DMSO) toxicity mediated release of free hemoglobin, red cell and white cell lysates, chemo-
kines and cytokines that may cause hemodynamic destabilization. Some of the recent devel-
opment and data are reviewed.
While every step from collection to infusion of CB impacts engraftment and ultimately patient
survival, in this chapter, we will focus on the roles of processing and post-thaw manipulations.
2. Processing
The world’s first CB banks were established at the New York Blood Center, Düsseldorf and
Milan in 1992 [13]. Initially, CB was processed and cryopreserved as whole cord blood, which
we refer to in this chapter as zero generation process [19]; however, in 1995, Rubinstein et al.
pointed out that “the first problem is that stockpiling (“banking”) a sufficiently large number
of cryoprotected Whole PCB (placental cord blood) units requires vast amounts of costly
storage space in liquid nitrogen (LN). To establish an adequate panel, therefore, the hemato-
poietic cells of PCB units need to be concentrated into units of much smaller volume.”[13] It
was for this reason that volume reduction processing of CB units was developed, with
associated reduction of the ‘bulk of the erythrocytes and plasma’. It was reported that the red
blood cell (RBC) reduction processing method increased the number of units that could be
stored in the same freezer space by as much as 10-fold, and thus provided significant economic
advantage [13].
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Rubinstein et al. reported in 1998 the first comparison of engraftment rates using RBC-replete
units (whole CB) and RBC-reduced (RCR) units [19]. In their Table 2, they indicated that the
majority of patients in their series (337 of 546 patients) were transplanted with whole CB that
were RBC-replete, and of the 365 patients (out of 546 patients) who had myeloid engraftment,
the Kaplan-Meier engraftment rate was 80% [95% confidence interval (CI) 75–85%] among the
RBC-replete CB transplant recipients, and 82% with RCR units (95% CI 76–88%). Whether the
unit used for the transplants was RBC-replete or RCR was not considered among the variables
associated with the engraftment- and transplantation-related events.
Many volume reduction methods of processing umbilical CB which reduce RBCs prior to the
cryopreservation have been considered since then (Table 1); however, the most common
method for processing CB units today is the hetastarch or HES RBC reduction (RCR), whether
manual or automated. For the sake of convenience, we will call these first generation (1st Gen)
cord blood processing techniques. It should be noted that these methods are often erroneously
referred to as red cell depletion when all of these techniques retain considerable RBCs and do
not deplete, but only reduce the number of RBCs.
Unfortunately, all 1st Gen RCR processing methods lose significant numbers of nucleated
cells, stem cells, and progenitor cells as measured by CD34+ cells or colony forming units
(CFU) enumeration, with an approximately 25% nucleated cell loss on average among vari-
ous reports in the literature [10–17] and a range of 14–42% for the various methods reported
by Takahashi et al. [10]. This is of concern because it is well-known that the success of CBT
is critically dependent on cell dose, and insufficient cell dose is widely regarded as the most
important limitation for umbilical CB transplantation, especially for adults and large chil-
dren [1, 3]. Table 1 lists some of the most common 1st Gen CB processing techniques.
Technique Manual/automated
processing
RBC
reduction 
Plasma
depletion/
reduction
Zero generation Whole cord blood Manual None None
First generation hetastarch Red cell reduced Manual SEPAX* or
AXP-Express*
Yes Yes
First generation PrepaCyte Red cell reduced Manual Yes Yes
First generation Top & bottom Optipress II Red cell reduced Manual Yes Yes
First generation Ficoll Red cell reduced Manual Yes Yes
MaxCell (MC) Technologies
Second generation Plasma depleted/
reduced
Manual
SEPAX
No Yes
Third generation MaxCord
RBC Reduced + RBC
Replete
Manual
SEPAX
AXP-Express
Yes/No Yes
* Proprietary Technologies: SEPAX from BioSafe; AXP-Express from Thermogenesis; MaxCell 2nd Gen from StemCyte;
MaxCell 3rd Gen from CyteTherapeutics, Inc.
Table 1. Technical comparison of some of the most popular 1st Gen CB processing techniques and the proprietary 2nd
and 3rd MaxCell CB processing technologies.
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To maximize CB cell dose, R. Chow has developed two proprietary alternative CB volume
reduction technologies (2nd Gen and 3rd Gen) which he calls MaxCell CB processing tech-
nologies, because both share the common characteristics of (1) depleting or reducing plasma,
(2) maximizing stem cell, progenitor, nucleated and mononuclear cell recovery after processing
and most importantly, and (3) having identical cellular composition upon infusion for one
version of the third generation technology (Tables 1–3).
Post-processing
recovery cell #
recovery %
Volume
(ml)
Frozen volume
(ml)
RBC
(ml)
DMSO (g) 5% Dextran-40
(ml)
6% HES
(ml)
CPD—Plasma
(ml)
RCR
Gen 1-HES
20–28 25–35 Varies
1–15
1.25–1.75 2.3–3.5 <10, if present Varies
4–15
MaxCell
Gen 2
40–84 50–100 28–70 5.0–10.0 10–20 0.0 10–12
MaxCell
Gen 3
20–28
40–84
25–35
50–100
1–15
28–70
1.25–1.75
5.0–10.0
2.3–3.5
10–20
<10, if present 4–15
10–12
1st generation RBC-reduced CB Products—Manual: Hetastarch most commonly used; however, also include
PrepaCyte, Optipress, Ficoll Hypaque; Automated: Sepax & AXP-AutoXpress.
MaxCell: 2nd generation plasma depleted/reduced CB products and 3rd generation MaxCord CB products.
Table 2. A comparison of the volumes and amount of some of the various components of first (hetastarch), second and
third generation CB technologies.
The MaxCell second generation (2nd Gen) technology or plasma depletion/reduction reduces
or depletes plasma without reducing RBCs. Plasma is removed or reduced from the product
prior to the cryopreservation [18]. Although the resulting volume of CB products processed
by such a method is two to three times larger, 2nd Gen results in greater than 99.9% processing
recovery of nucleated cells and all critical cell types prior to the testing and archival sampling.
True nucleated cell loss was less than 0.01% from 2nd Gen CB processing, as evidenced by
complete blood count (CBC) enumeration of the discarded plasma fraction. In practice, because
of the testing and archival sampling, the actual loss will be raised to around 5–10% of the
collected CB cell dose. Such minimal loss was reproducible from validation to an actual
MaxCell inventory of more than 12,000 CB products that had pre- and post- processing CBC
available. Even after thawing, in 188 post-thaw segment samples, a median of 90.33% post-
sampling/post-thaw TNC recovery and a median of 91.84% post-sampling/post-thaw CD34 cell
recovery of preprocessing values were achieved for 2nd Gen CB products. The resultant
volume, DMSO load, RBC, WBC and RBC lysate content of 2nd Gen CB products are similar
to cryopreserved peripheral blood products (Tables 1–3).
The newest MaxCell technology, MaxCord processing technology, referred to as third gener-
ation (3rd Gen) CB processing technology in this chapter, combines the advantages of ease and
convenience of thawing for the 1st Gen products and maximum stem (VSEL), progenitor (CFU
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and CD34+), nucleated, and mononuclear cell recovery of the 2nd Gen, without any of the
associated disadvantages. While the processing methods and cryopreserved products are
distinctly different, with the preferred embodiment of 3rd Gen technology, the cellular
compositions of the final infused products are virtually identical between the two MaxCell
technologies. Table 2 outlines some of the component differences in volume, RBC content, and
amount of additional components, such as DMSO, dextran-40, HES, and anticoagulant CPD.
Post-processing 
Recovery
Cell #
Recovery %
RBC (×1010) Total
nRBC
(×107)
Total
MNC
(×107)
TNC
(×107)
CD34+
cells
(×106)
Viability
(%)
CFU-
GM
(×105)
CFU-E
(×105)
CFU-
GEMM
(×105)
Total
CFU
(×105)
Total
VSEL
(×103)
RCR
Gen 1- HES
8
32.9%
2.1
78.1%
26
80.7%
65.77
78.7%
1.16
84.0%
96%
98.3%
3.5
42.1%
3.6
48.5%
4.6
50.4%
11.7
47.1%
4.434
54.6%
MaxCell
Gen 2/3
Gen 2–24
100.2%
Gen 3–8
33%
2.5
91.5%
31
92.4%
81.56
96.4%
1.42
99.9%
98%
99.3%
7.8
78.1%
4.7
111.2%
9.3
88.4%
21.8
88.1%
8.134
100.1%
Gen 2 and/or 3
MaxCellGen/
RCR
Recovery Ratio
Gen 2
312%
Gen 3
100–312%
118% 117% 124% 121% 102% 225% 128% 202% 186% 181%
P value Gen 2
<0.0001
Gen 3
Variable
0.18 0.27 0.002 0.003 0.24 0.05 0.50 0.001 0.01 0.007
Comparisons between HES 1st Gen and MaxCell 2nd and 3rd Gen are performed using parallel processing
comparison using one half of the same cord blood unit for first generation hetastarch and the other half for MaxCell CB
Products [18]. Cell types which exhibit significant differences are highlighted by boldfaced fonts.
Second and third generation cord blood products have similar yield for all cell lineages, and only differ in the final
RBC yield depending on the embodiment of 3rd Gen used. Third generation is similar to first generation in RBC
reduction in RBC reduction. Sample size n = 10 for all the cell types, except for VSEL, which had a sample size n = 3. P
values are calculated using the paired-sample t-test.
Table 3. Stem cell (VSEL), progenitor cell (CFU and CD34+), nucleated cell, mononuclear cell, nucleated RBC, RBC, and
viability recovery of 1st (hetastarch method) MaxCell 2nd and MaxCell 3rd generation CB processing.
Third generation CB processing technology is perhaps the most flexible CB processing
technology developed to date, with the additional option to reduce RBCs without losing
as much stem, progenitor, nucleated, and mononuclear cells as 1st Gen RCR techniques
(Table 3). Table 1 highlights some of the processing technical differences among various
popular 1st Gen techniques versus 2nd Gen and 3rd Gen CB processing technologies. Un-
like Chow’s 2nd Gen CB technology which is only amenable to SEPAX-automated process-
ing and not accessible to AXP-Express, Chow’s latest MaxCell technology can be
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automated using both SEPAX or AXP-Express. Table 3 shows the differences in CB stem
cell (VSEL), hematopoietic progenitor cell (CD34+ and CFUs), total nucleated cells (TNC),
mononuclear cells, nucleated RBCs (nRBC), RBCs, and viability between the 1st Gen HES
technique and the proprietary MaxCell 2nd/3rd Gen technologies. While the processing
methods and cryopreserved products are distinctly different, the cellular composition of
the final infused product is identical between the two MaxCell technologies using the pre-
ferred embodiment of 3rd Gen (Table 3) technology, while other embodiments can be
adapted to reduce RBC, free hemoglobin, DMSO, and WBC lysate load for certain situa-
tions to better suit the needs of the individual patients (Table 2).
Barker et al. [20] have questioned whether the MaxCell data [8] indicating significantly higher
TNC doses with red cell-replete MaxCell CB products are meaningful. Indeed, it was specu-
lated that a ‘correction factor’ of 0.75 should be applied to the reported TNC content of RBC-
replete products, arguing that such products contain the noncritical nucleated RBC (nRBC)
and neutrophils, and implying that critical stem and progenitor cells are somehow not retained
to a similar extent as TNC. Unfortunately, no hard data accompanied this implication or their
recommendation and the authors ignored the data on tens of thousands of CB units presented
by Chow et al. [18] in Table I–IV of their paper, which showed significantly higher recovery
of stem (VSEL), progenitor (CD34+ and CFU), nucleated and mononuclear cells with parallel
processing of the two halves of the same CB units using MaxCell 2nd Gen technologies versus
RCR techniques. More importantly, the superior outcome data for the MaxCell CB products
[8] were similarly disregarded. Petz and Chow [21] pointed out that implementation of Barker’s
recommendation, if incorrect, would underestimate the progenitor cell content of RBC-replete
CB products, resulting in the inappropriate rejection of certain optimal units by transplant
physicians in favor of RCR products with an apparently higher TNC dose after application of
the ‘correction factor’ for RBC-replete products.
1st generation RCR 2nd/3rd generation MaxCell
Neutrophil ANC500 engraftment ~75–80% ~85–90%
Overall survival ~40–45% ~57–75%
This outcome assumes that large cord blood banks have normal and similar distribution of patients, disease
indications, and disease stage.
Table 4. Published overall clinical outcome of CBT patients receiving RCR CB products from NYBC, COBLT, NMDP,
and CIBMTR [19, 23–34] versus MaxCell CB products from CIBMTR audited outcome data [8].
To study this issue, Chow et al. divided 10 CB units in half and processed one half by RCR
using the most commonly used hetastarch method, and the other half by MaxCell in parallel
[18]. As indicated in Table 3, the average TNC of MaxCell CB products after processing was
124% of that in RCR units (p = 0.002). Moreover, MaxCell caused virtually no loss of CD34
cells compared to RCR produced CB, with the mean post-processing CD34 cell count in
MaxCell products being 121% of that in RCR units (p = 0.003). Page et al. [22] have reported
on their experience with 435 CB transplants and concluded that total CFU is the best predictor
Cord Blood Stem Cell Processing, Banking and Thawing
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of engraftment. Of major importance is that the mean recoveries of CFUs were also higher
for MaxCell products [11], as shown in Table 3, 225% for CFU-GM (p = 0.05), 202% for CFU-
GEMM (p = 0.001) and 186% for total CFU (p = 0.01). Taken together, this means that CFU,
the most important cellular predictors of engraftment success, showed an even bigger
difference than TNC between RCR and MaxCell products, in contrast to the speculation by
Barker and NYBC [20].
In fact, in clinical studies of MaxCell CB products, outstanding clinical outcome in terms
of engraftment and patient survival have been achieved. Table 4 showed published
engraftment and survival outcome for transplantation using 1st Gen RCR CB products from
diverse CB banks (NYBC, EuroCord, COBLT CBB, London CBB, French CBB) or large
outcome data registries, such as CIBMTR or NMDP [19, 23–34] versus 2nd/3rd Gen Max
Cell CB products [8].
Ballen et al. [34] studied the outcome of manually processed RCR CB products, automated
processed RCR CB products, and manually processed MaxCell 2nd Gen CB products. While
acknowledging some of the significant design flaws in their study, the authors concluded that
automated processing systems resulted in higher day-28 neutrophil recovery than manually
processed plasma-reduced products; however, overall survival by day-100 was not different
among the three groups. Many study decisions and design issues were not clearly explained
or delineated in this study, such as patient selection or study end point selection. For patients
receiving Max Cell 2nd Gen CB products and manually processed RCR CB products, there
were only 133 and 279 patients, respectively, when hundreds to thousands more were
available fitting the study criteria during the study period for both of these groups. For
example, even in a 2008 study with just pediatric hematological malignancy patients from
one transplant center (U. Arizona) and one CBB (StemCyte), Graham et al. presented data for
105 matched pairs of patients from 128 patients transplanted with PDR 2nd Gen CB and 112
patients transplanted with RCR 1st Gen CB [35]. In fact, it is obvious that of the 16 public CB
banks in the study, at least four of the banks each alone had more patients fitting the exact
criteria for patients transplanted with manually processed CB in the study, so the reasons
why these other patients were not selected and the reasons for inclusion of the particular
patients in the study were not clear. The decision to use only 100-day survival, and not 1-
year, 3-year, or 5-year overall survival, was also quite unconventional. All three patient groups
had approximately 80% 100-day overall survival, which should not give an erroneous
impression that long-term survival is that high or that long-term survival may be the same
for all three groups. Previous studies with far larger patient populations not restricted to
acute leukemia/MDS from NYBC, COBLT, CIBMTR, and NMDP have confirmed that
transplants with RCR CB yielded around 40–45% 1-year survival and much higher 100-day
transplant-related mortality [19, 23–33]. Indeed, long-term survival data on many more
patients fitting the study criteria were available from CIBMTR, NMDP, and the various banks
when the study was analyzed, so it was odd that 100-day overall survival (OS) was chosen
as one of the study’s primary end points, when it would have been far more meaningful and
just as easy to calculate and show longer term survival and transplant-related mortality data,
as is typical for such CIBMTR studies. In fact, our experience of a large MaxCell CB bank
Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine10
with thousands of patients transplanted with its products have shown that survival or
transplant-related mortality during the first 100 days is often not predictive for long-term
survival or patient mortality [8, 35–43].
The most rigorous method to address clinical outcome differences between different types of CB
processing methods would be to conduct prospective double-blind placebo-controlled clinical
trials; however, in HSCT, this is largely not feasible. Instead, matched-pair analyses allow for
comparisons that are reasonably free from extraneous factors. To investigate rigorously whether
clinical outcome differences exist between RCR and MaxCell CB products, Chow and collabo-
rators performed matched-pair analysis using retrospective outcome data. Moreover, they
secured an independent third party’s assistance from CIBMTR to audit the outcome data with
patient chart review on site at transplant centers using an audit design proposed by CIBMTR and
finding the MaxCell CB outcome data to be 97.3% accurate, with no errors in survival, mortality,
or engraftment. For both studies, all thalassemia and pediatric hematological malignancy
patients were included and outcome were similar before and after matched-pair comparisons.
A logistic regression model was used to find patients with similar characteristics to form pairs.
For both studies, cumulative incidence was used for ANC500 neutrophil and platelet 20K and
50K engraftment. Kaplan–Meier was used for overall survival, disease-free survival, transplant-
ed-related mortality, and relapse or autologous recovery. Cox regression analysis, log-rank test,
univariate comparisons and the paired Prentice-Wilcoxon method were performed to compare
the two matched-pair groups. Using the above methodologies, two rigorous retrospective
matched-pair analysis of patients using RCR versus MaxCell CB products were conducted for
thalassemia as well as for pediatric hematological malignancy patients [35–38].
RCR 1st Generation CB MaxCell 2nd/3rd generation CB
1-Yr Overall Survival
Thalassemia Matched Pair
Matched Pair 53 ± 18 %
Univ. RR = 0.09; p = 0.03
PPW Test p = 0.001
Matched Pair 96 ± 4 %
Univ. RR = 0.09; p = 0.03
PPW Test p = 0.001
1-Yr Disease-Free Survival
Thalassemia Matched Pair
30 Pairs
Matched Pair 40 ± 15 %
Univ. RR = 0.17; p = 0.01
PPW Test p = 0.0001
Matched Pair 89 ± 6 %
Univ. RR = 0.17; p = 0.01
PPW Test p = 0.0001
1-Yr Transplant-Related Mortality
Thalassemia Matched Pair
30 pairs
Matched Pair 47 ± 18 %
Univ. RR = 0.09; p = 0.03
PPW Test p = 0.001
Matched Pair 4 ± 4 %
Univ. RR = 0.09; p = 0.03
PPW Test p = 0.001
Relative Risk calculated by Cox Regression for Univariate Analysis, with Red Cell Reduced CB products as reference.
PPW = Paired Prentice-Wilcoxon test used in comparing matched-pair patients [35–38]. Absolute Neutrophil Count
(ANC 500) is the first day of 3 consecutive days of an absolute neutrophil count equal to or greater than 0.5 × 109/L
prior to day 60 after transplantation (ANC 500)) engraftment. Platelet 20K engraftment is the first day of 7 consecutive
days of a platelet count equal to or greater than 20 × 109/L prior to the day 180 after transplantation.
Table 5a. Matched-Pair Comparison of Clinical Outcome of Patients transplanted with First Generation Red Cell
Reduced CB Products versus MaxCell 2nd/3rd Generation CB products—30 pairs of thalassemia patients [36, 38] (Jaing
et al. 2008) and 105 pairs of pediatric malignancy patients [35, 37, 38] (Jaing et al. 2008).
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RCR 1st Generation CB MaxCell 2nd/3rd Generation CB
ANC500 Neutrophil Engraftment
Pediatric Leukemia Matched Pair
92 pairs
85 ± 6 %
Univ. RR = 0.81; p = 0.06
Log-Rank Test p = 0.12
Matched Pair 87 ± 6 %
PPW p=NS
89 ± 6%
Univ. RR = 0.81, P = 0.06
Log-Rank Test p = 0.12
Matched Pair 91 ± 7%
PPW p=NS
Platelet 20K Engraftment
Pediatric Leukemia Matched Pair
55 ± 6 %
Univ. RR = 1.60; p = 0.007
Log-Rank Test p = 0.006
Matched Pair 56 ± 6 %
Matched Pair PPW p = 0.001
69 ± 6 %
Univ. RR = 1.60; p = 0.007
Log-Rank test p = 0.006
Matched Pair 71 ± 7 %
Matched-Pair PPW p = 0.001
Platelet 50K Engraftment
Pediatric Leukemia Matched Pair
51 ± 6 %
Univ. RR = 1.41; p = 0.06
Log-Rank Test p = 0.05
Matched Pair 52 ± 6%
Matched-Pair PPW p = 0.007
65 ± 5 %
Univ. RR = 1.41; p = 0.06
Log-Rank Test p = 0.05
Matched Pair 68 ± 7 %
Matched-Pair PPW p = 0.007
1-Yr Overall Survival
Pediatric Leukemia Matched Pair
48 ± 5 %
Univ. RR (death) = 0.74; p = 0.01
Log-Rank Test p = 0.11
Matched Pair 50 ± 5%
Matched-Pair PPW p = 0.005
61 ± 4 %
Univ. RR (death) = 0.74; p = 0.01
Log-Rank Test p = 0.11
Matched Pair 68 ± 5%
Matched-Pair PPW p = 0.005
1-Yr Disease-Free Survival
Pediatric Leukemia Matched Pair
46 ± 5 %
Univ. RR (death) = 0.86; p = 0.11
Log-Rank Test p = 0.41
Matched Pair 47 ± 5%
Matched Pair PPW p = 0.07
54 ± 4 %
Univ. RR (death) = 0.86; p = 0.11
Log-Rank Test p = 0.41
Matched Pair 61 ± 6%
Matched Pair PPW p = 0.07
1-yr Transplant-Related Mortality
Pediatric Leukemia Matched Pair
45 ± 5 %
Univ. RR = 0.49; p < 0.001
Log-Rank Test p = 0.002
Matched Pair 44 ± 5%
Matched-Pair PPW p = 0.0001
23 ± 4 %
Univ. RR = 0.49; p < 0.001
Log-Rank Test p = 0.002
Matched Pair 17 ± 4%
Matched-Pair PPW p = 0.0001
Relative Risk calculated by Cox Regression for Univariate Analysis, with Red Cell Reduced CB products as reference.
PPW = Paired Prentice-Wilcoxon Test used in comparing matched-pair patients [35–38]. Absolute Neutrophil Count
(ANC 500) is the first day of 3 consecutive days of an absolute neutrophil count equal to or greater than 0.5 × 109/L
prior to day 60 after transplantation (ANC 500)) engraftment. Platelet 20K engraftment is the first day of 7 consecutive
days of a platelet count equal to or greater than 20 × 109/L prior to the day 180 after transplantation.
Table 5b. Matched-Pair Comparison of Clinical Outcome of Patients transplanted with First Generation Red Cell
Reduced CB Products versus MaxCell 2nd/3rd Generation CB products—105 pairs of pediatric malignancy patients [35,
37, 38].
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For the thalassemia matched-pair study, 48 patients and 10 patients transplanted with MaxCell
CB and RCR CB, respectively, and 3 MaxCell CBT patients were matched to each RCR CBT
patients to form 30 pairs [36, 38]. Outcome comparisons of the two patient groups pre-match
showed superiority in overall survival, disease-free survival, and transplant-related mortality
for patients transplanted with MaxCell CB. Factors matched between the two groups were age,
weight, #HLA matches, TNC dose, and transplant center experience. As the patients are mostly
pediatric, there were no differences in median TNC between the two patient groups before
(MaxCell 9.1 versus RCR 8.9 × 107/kg) or after the match (MaxCell 9.1 versus RCR 8.9 × 107/kg).
Table 5 showed significant improvement in 1- to 3-year overall survival and disease-free
survival and 1-year and 3-year transplant-related mortality with the use of MaxCell CB for
thalassemia patients [36, 38]. Interestingly, neutrophil engraftment, and short-term (100-day)
survival or transplant-related mortality were not significantly different between MaxCell and
RCR CB products.
For the pediatric hematological malignancy matched-pair study, factors matched between the
two groups were age, weight, #HLA matches, TNC dose, disease, and disease status [35].
Combining audited outcome data from one CBB (StemCyte) and data from one transplant
center (U. Arizona), Graham et al. presented data for 105 matched pair of patients (paired from
128 patients transplanted with MaxCell 2nd Gen CB and 112 patients transplanted with RCR
1st Gen CB). Table 5 shows that for the 105 pairs of pediatric hematological malignancy
patients, 1- and 3-year overall survival, 100-day, 1-year and 3-year transplant-related mortality,
and platelet (20K and 50K) engraftment were significantly improved with the use of MaxCell
CB, while disease-free survival trended towards improvement [35, 37, 38]. Superior outcome
of the MaxCell CB patient group in pre-match comparisons were confirmed by the results seen
in the matched-pair analysis. Again, neutrophil engraftment and short-term (100-day) survival
or transplant-related mortality were not significantly different between MaxCell and RCR CB
products despite significant advantages in platelet engraftment, overall survival and trans-
plant-related mortality.
Using data supplied by the NMDP for its large CB inventory of its CBB network (as of June
30, 2006) derived from almost 50,000 units (10,912 MaxCell and 38,819 RCR), Chow et al. [8]
showed that a 24% superior nucleated cell recovery amplified into a 200% increase for
MaxCell over RCR for the proportion of the inventories with products that had TNC counts
higher than 150 × 107 (20% versus 10% of the inventory; test for difference in proportions, p
< 0.0001) and a threefold difference for the proportion of products that had TNC counts
higher than 200 × 107 (6% versus 2% of the inventory; test for difference in proportions, p <
0.0001). Therefore, the effectiveness of MaxCell CB processing is supported by data derived
from the NMDP CB inventories of almost 50,000 units, which proves that the MaxCell CB
inventories have significantly higher proportions of products with high TNC doses than the
RCR CB inventories. Indeed, the MaxCell CB inventories had two to three times the
proportion of high-cell dose products with TNC number of 150 × 107 or above and 200 × 107
or above (p < 0.0001) than the inventories of RCR units. Thus, MaxCell CB processing
provides more efficient utilization of this valuable resource. This would seem to be particu-
larly significant for those patients who participate in directed CB donation and private
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banking, because of the uniqueness of the cellular content and the importance of cell dose
in outcome of HSCT.
3. Thawing of cryopreserved CB products
Unlike cryopreservation, thawing should be performed as quickly as possible by immersing
the body (but not the ports) of cord blood bag in a 37°C water bath to an icy slush mixture.
After thawing, there will be invariably some cell lysis, including 5–20% of the RBCs [44], a
certain amount of WBC, principally neutrophils which do not survive freezing and thawing
well, and occasional cell clumping and viscosity due to the release of chromosomal DNA.
Table 6 shows the expected cell loss for the various 1st Gen methods [44] as well as for the
MaxCell 2nd/3rd Gen technologies [8]. The published cell loss and death associated with
the CB processing method is listed below in Table 6, which showed the least TNC, CD34,
and CFU loss for MaxCell CB products, followed by PrepaCyte, and with AXP-Express
coming in last of the four techniques tested by Akel et al. [44]. Screnci et al. [45] independ-
ently confirmed that 42 un-manipulated RBC-replete CB products had significantly better
post-thaw and wash recovery of TNC than 36 RCR CB, 95.2 ± 14.7% versus 85 ± 15.4% (p
= 0.004).
Red cell reduction 1st generation MaxCell 2nd/3rd
generation
Hetastarch* Prepa
Cyte-CB*
Sepax*  AXP* MaxCell**
(n = 188)
TNC 18%
vs. PrepaCyte
p < 0.01
vs. Sepax
p < 0.05
14%***
vs. MaxCell
p = 0.004
10% 14% 20%
vs. PrepaCyte
p < 0.001
vs. Sepax
p < 0.01
8.89%
4.8%***
Total MNC 8% 13% 7% 20% <10%
CD34+ Cells 32% 24% 19% 37% 8.12%
CFU 47%
vs. PrepaCyte
p < 0.05
20% 37% 53%
vs. PrepaCyte
p < 0.001
<10%
Viable NCs
by Trypan Blue
32% 28% 27% 22% Variable depends on
#neutrophils in CB
Table 6. Post-thaw cell loss vs. pre-freeze cell count [11**, 44*, 45***].
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4. Post-thaw manipulations
There are generally three main methods of manipulations after thaw of CB products, with
many variations among different banks and transplant centers. Table 7 summarizes whether
each method reduces the total amount or just dilutes the concentration of DMSO, free hemo-
globin or WBC lysates from thawing, safe thaw-to-dilution and thaw-to-infusion times, as well
as summarizes the advantages and disadvantages of each method. Automated procedures
using the Biosafe Sepax system can be used on all CB product types and was shown to be as
effective as manual washing in terms of cell recovery and viability [46]. The Duke group found
equal TNC recovery, identical viability, among 30 Sepax and 195 manual washed products with
slightly better CFU and lower CD34+ recovery for the Sepax products [47].
Reduced total mass Reduced concentration Safe thaw-to-dilution time
Safe thaw-to-infusion time
Reduced
DMSO
Reduced
Free Hgb
Reduced
WBC
Diluted
DMSO
Diluted
Free Hgb
Diluted
WBC
RCR MaxCell
2nd Gen
MaxCell
3rd Gen
Bedside Thaw/
Direct Infusion
No No No No No No 30 min
30 min
10 min
10 min
30 min
30 min
Dilution/
Reconstitution
No No No Yes Yes Yes 30 min
4 hr
10 min
1 hr
30 min
4 hr
Dilution/wash Yes Yes Yes Yes Yes Yes 30 min
8 hr
10 min
2 hr
30 min
8 hr
Table 7a. Comparisons of the three major CB product thaw methods and the various parameters, Pros and Cons. [8, 21,
44, 48].
Pros Cons
Bedside Thaw/
Direct Infusion 
*In matched-pair analysis of 258 patients
forming 129 pairs of non-washed versus
washed patients (95 malignancy pairs & 34
nonmalignant indication pairs), Direct
Infusion of MaxCell CB resulted in
IMPROVED OS, DFS, TRM, ANC 500, platelet
20K and platelet 50K engraftment,
Higher Limited cGvHD but Lower Extensive
cGvHD *Minimum cell loss if within safe
thaw-to-infusion time
*Immediate infusion necessary, within first 10 min
preferably for minimum additional cell lysis due to
DMSO toxicity. Not longer than 30 min.
*Highest Load & Concentration of DMSO, RBC &
WBC lysate
*No addition of extra stabilizing agent
*Inability to assess product characteristics in the
freezing bag; however, product characteristics in the
attached segment can be used as a surrogate.
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Pros Cons
*Minimum infusion volume
*Least technically challenging—with most
important element being control of thaw-to-
infusion time *Similar to other cryopreserved
cellular product *Recommended Thaw
Method for MaxCell CB Products by
Manufacturer for most situations.
*Potential for AE if used improperly not according
to Manufacturer’s Validated & Recommended
Protocol.
Dilution/
Reconstitution 
*More time from thaw to infusion
*Controlled Thaw in Cell Therapy Lab
*Hyperosmolar re-equilibration resulted in
Diluted (though Equal Amount of)
DMSO, Free Hgb, RBC & WBC lysate as Direct
Infusion/Bedside Thaw *Recommended Thaw
Method for 1st
Gen RCR CB Products by some CB banks
*Largest infusion volume of three methods
*Same total mass of DMSO, Free Hgb, RBC & WBC
lysate as Direct Infusion/Bedside Thaw
*Initial Dilution Step should be performed
preferably within the first 10 minutes, in no case
longer than the first 20 minutes for MaxCell CB and
30 minutes for RCR CB.
*Potential for AE if used improperly not according
to Manufacturer’s Validated & Recommended
Protocol.
Dilution/Wash  *Removal of more than 80% DMSO and RBC
and WBC Lysate
*Removal of Hetastarch, PrepaCyte or other
colloidal agents
*Longest Safe Thaw to Infusion Time as long as
the initial dilution is performed within
the first 10 minutes *Recommended Thaw
Method for 1st Gen RCR CB Products by some
CB Banks
*Recommended 1:7 Dilution-Wash Thaw
Method for MaxCell CB products by
Manufacturer for certain situations.
* Compared to Direct Infusion, Dilution/Wash of
MaxCell CB resulted in Worse OS, DFS, TRM, ANC
500, Platelet 20K and Platelet 50K engraftment,
Lower Limited cGvHD but Higher
Extensive cGvHD.
*Most significant cell loss of three methods during
discard of post-centrifugation supernatant
*Risk of bag breakage
*Risk of cell aggregation with centrifugation
*Longest time and highest technical complexity of
three methods
*Initial Dilution Step should be performed
preferably within the first 10 minutes,
in no case longer than the first 30 mins
*Potential for AE if used improperly
not according to Manufacturer’s
Validated & Recommended Protocol.
Table 7b. Pros and Cons of the three major CB product thaw methods [8, 21, 44, 48].
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4.1. Bedside thaw/direct infusion method
The CB product is thawed at bedside using the above thaw technique and immediately
administered to the patient. Thaw to completion of infusion is typically completed within 10
min, with a maximum of 20 min, to avoid DMSO-induced toxicity and lysis of cells. Cell loss
and technical complexity are minimal for bedside thaw/direct infusion of the three main thaw
methods, especially if the infusion bag is flushed with saline or another approved infusion
fluid to rinse out and inject the residual cells. Delay in infusion after thaw will lead to DMSO
toxicity and cell lysis, resulting in loss of cell viability and release of potentially harmful
cytokines, chemokines and cell debris that may potentially cause adverse events if released in
sufficient amount. For all of the SAE reported to NMDP for CB infusion in 2008–09, prolonged
thaw to dilution or infusion (essentially in vivo dilution) times were the common element
among all the cases (NMDP, unpublished data). Further clinical data from the St. Louis bank’s
transplanted CB from the same publication [48] showed that the no-wash direct infusion
provided the best post-thaw TNC recovery (median 99.0%, mean 85.6%, p < 0.01) and viability
(median 95.0%, mean 89.3%, p < 0.01) over no-wash dilution (TNC recovery median 78.0%,
mean 78.4%, viability median 88.0%, mean 84.8%) and post-thaw wash (TNC recovery median
78.6%, mean 77.4%, viability median 73.0%, mean 74.0%) [48].
There has been some concern that the presence of residual RBC in cryopreserved MaxCell CB
may adversely affect the safety of HSCT; however, lysed RBC ghosts and free hemoglobin do
not usually give rise to severe problems [49] unless a patient has compromised renal function
or is on nephrotoxic drugs. The rare occurrences of acute renal failures with HSCT are
frequently self-limiting or resolved with dialysis. While MaxCell manufacturers have always
advocated direct infusion without post-thaw washing or dilution for most patients receiving
MaxCell CB products, they also caution that for children, small patients, patients with
compromised renal function (pre-existing or iatrogenic), patients with known sensitivity to
DMSO, RBC or WBC lysates, chemokines and cytokines, and, lastly, for transplant centers that
cannot directly infuse MaxCell CB products within 10–20 min of thawing, post-thaw washing
is indicated. If post-thaw reconstitution or washing is to be performed, then it is of utmost
importance to dilute the MaxCell CB product adequately (serial 1:1 dilutions three times to 1:7
final minimal dilution) within 10 min of thawing and to complete infusion of the washed
product within 1–2 h, respectively (Table 7). The lack of SAEs when MaxCell CB products are
thawed using strictly either the manufacturer’s direct infusion method or post-thaw washing
procedures or following proper validated good thawing practices has been documented [8].
Chow et al. [50–55] showed that for MaxCell CB products, direct infusion resulted in superior
1-year and 3-year overall survival, disease-free survival, and transplant-related mortality, as
well as neutrophil ANC500 and platelet 20K and 50K engraftment, with higher limited cGvHD
but lower extensive cGvHD over post-thaw wash [50–54]. Table 8 shows the results of bedside
thaw/direct infusion compared to post-thaw wash methods for MaxCell CB products in a
matched-pair analysis of 258 patients forming 129 pairs of non-washed versus washed patients
(95 malignancy pairs and 34 nonmalignant indication pairs), which confirmed the pre-match
observations that direct infusion of MaxCell CB resulted in improved neutrophil ANC500 and
platelet 20K, and 50K engraftment, as well as higher 1-year and 3-year overall survival, disease-
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free survival, and lower transplant-related mortality, over transplants where MaxCell CB was
post-thaw washed. Lastly, higher limited cGvHD with lower extensive cGvHD of direct
infusion will maximize graft-versus-leukemia effect (GvL) without the increased mortality
associated with severe cGvHD [55–59].
Paired Prentice-Wilcoxon test and log-rank tests were used to analyze 258 patients forming 129 pairs; (95 pairs
malignancies and 34 pairs nonmalignant indications; relapse calculations are only for the 95 malignancy pairs).
Paired Prentice-Wilcoxon test uses matched pairs of patients infused with post-thaw washed versus unwashed
MaxCell CB products. Log-rank tests used univariate analysis of previously matched patients.
Table 8. Matched-pair analysis results comparing 129 pairs of 258 CBT patients receiving unwashed versus washed
MaxCell CB products [56–59].
4.2. Dilution and wash thaw method
In 1995, Rubinstein et al. [13] described a thaw method, which consisted of slow reconstitution
of the thawed unit three times with an equal volume of isotonic solution (5% [wt/vol] dex-
tran-40/2.5% [wt/vol] human serum albumin) to an eventual ratio of 1:7 product:diluent (1:1
→ 1:3 → 1:7), followed by centrifugation at 4°C at 400 × g for 10 min. The supernatant,
containing DMSO, hetastarch (if applicable), cell lysates, hemolysate (including free hemo-
globin), and any chemokines and cytokines released up to that point, are removed and cellular
sediment is resuspended in one volume of fresh isotonic infusion solution equal to or greater
than the original product volume. For all products, this method achieves post-thaw stability
in cases of prolonged thaw-to-infusion time and reduces the potential for infusion reactions,
by significantly reducing the amount of DMSO, hetastarch (if applicable), cell lysates, hemo-
lysate (including free hemoglobin), and any chemokines and cytokines. Moreover, according
to Rubinstein et al. [13], this method averts post-thaw osmotic damage and stabilizes cell
viability if the product is not infused immediately, and reportedly provided near total recovery
of CFU progenitors. A number of recent studies have failed to confirm the latter observation
as reviewed by Akel et al. [44]. The COBLT study reported no infusion-related toxicity without
addressing the recovery controversy [32]. Laroche et al. [60] found 18% TNC loss with the
dilution-wash method, with 11% loss due to the washing step alone. Other reports also show
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significant loss of 10–25% for TNC, CD34+ and CFU [44–48]. Importantly, Regan et al. [48]
showed that no-wash direct infusion provided significantly improved post-thaw TNC
recovery (median 99.0%, mean 85.6%, p < 0.01) and viability (median 95.0%, mean 89.3%, p <
0.01) over post-thaw wash (TNC recovery median 78.6%, mean 77.4%, viability median 73.0%,
mean 74.0%). This represents a significant 20% median TNC loss and 22% median viability
reduction for post-thaw wash. Recently, even the NYBC in their HEMACORD product insert
recommended a second centrifugation step for the supernatant to harvest some of the lost cells,
which is a revision of the original NYBC wash method [13]. Both COBLT and NYBC recom-
mends a final wash dilution ratio at 1:7.
Table 8 summarizes a comparison study comparing MaxCell CB products thawed and infused
with bedside thaw versus post-thaw wash and showed improvement in 1-year overall survival,
disease-free survival, transplant-related mortality, neutrophil, and platelet engraftment.
Interestingly, limited cGvHD was higher while extensive cGvHD was lower for patients
infused with unwashed MaxCell CB.
4.3. Reconstitution/dilution and no-wash method
The St. Louis CB Bank described a basic dilution and no-wash strategy [48]. Reconstitution
with 1:1 ratio and ≥1:2 ratio of dextran-human serum albumin stabilized the hetastarch-
processed RCR CB and PrepaCyte-CB, respectively, decreased viability loss with prolonged
thaw-to-infusion time (for up to 8 h for HES-RCR CB), limited wash-related cell loss, and
reduced preparation time and complexity. Barker et al. used a 1:4 ratio dilution and no-wash
procedure for 104 RCR and 3 MaxCell products without severe AE [9]. However, the St. Louis
group’s own data [48] showed that no-wash direct infusion provided significantly better post-
thaw TNC recovery (median 99.0%, mean 85.6%, p < 0.01) and viability (median 95.0%, mean
89.3%, p < 0.01) over no-wash dilution (TNC recovery median 78.0%, mean 78.4%, viability
median 88.0%, mean 84.8%). This represents a substantial 21% median TNC loss and 7%
median viability reduction for reconstitution compared to direct infusion.
Most CB banks now agree on the reconstitution, dilution, and washing solution composition
of one volume of 25% human serum albumin (HSA) mixed with five volumes of 10% low-
molecular-weight dextran 40), though the degree of CB product dilution varies between 2- and
16-fold. It should be noted that post-thaw washing or reconstitution can further reduce cell
dose and viability as shown above [48], and is recommended for RCR CB by some CB banks,
but not recommended by the manufacturer for MaxCell CB except in special circumstances
[18, 21]. Regan et al. [48] showed a greater reduction of viability, TNC, and CD34 for unwashed
and undiluted CB after 2 h in vitro. However, in clinical practice, direct infusion performed
with bedside thaw should always be performed within 10–20 min to avoid DMSO toxicity
(Table 6) and is almost never performed after such a prolonged post-thaw interval, making
such in vitro comparisons clinically irrelevant except in cases where CB product manufacturer’s
recommendation is not followed. Importantly, the manufacturer of MaxCell CB products
recommends completion of infusion of MaxCell CB products using the bedside thaw method
within 10 min of initiation of thawing for adults at 5–10 mL/min for a 75-mL product. Several
other groups have demonstrated that direct infusion without washing produces excellent
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results for CB thawing [44, 47, 48, 60–68]. Chow et al. [18, 21, 50–59] was the first group to
report superior clinical outcome with bedside direct infusion over post-thaw wash, with
improved neutrophil and platelet engraftment, reduced transplant-related mortality, de-
creased extensive cGvHD, increased limited cGvHD, and enhanced overall and disease-free
survival.
To address the question of whether the presence of residual RBC in the cryopreserved MaxCell
products may adversely affect the outcome of HSCT, we have previously reported on the
outcomes of 118 MaxCell CB transplants for patients with both hematological malignancies
and nonmalignant indications [8]. Our experience indicates a 90.3% cumulative incidence for
neutrophil (ANC500) engraftment, 75.5% for platelet 20K engraftment, 16.3% for 100-day
transplant-related mortality, 65.5% for 1-year overall survival, and 51.6% for 1-year disease-
free survival. This was followed by another series with 120 patients with nonmalignant
indications [39] with similar outcome. At this point, after thousands of MaxCell CB products
have been transplanted at around 300 transplant centers, that favorable experience reported
previously has been maintained [[18, 35–43, 50–59], Chow et al. unpublished observations].
5. Conclusion
Because of the two- to threefold increased availability of high-cell dose CB products as a result
of MaxCell CB processing, and the outstanding clinical outcome observed to date, it may be
appropriate to ask whether it is reasonable to discard all the stem cell, progenitor cell, nucleated
cell, and mononuclear cell in order to preserve storage space and reduce cost [13]. In fact, even
the space cost savings argument is probably negated by the increased potential revenue
generated from much higher availability of high-cell dose CB products. However, more
importantly, is whether depriving patients of the opportunity to access the same HLA-matched
CB products with higher cell doses can be justified in the name of economics. Cost, the original
reason NYBC developed these RCR techniques, appears to be insufficient [13] if cell dose and
in turn, clinical outcome and patient survival are compromised. As an example, a 25%
improvement in infused cell dose can take a product from a suboptimal 2.0 × 107 TNC/kg body
weight to an adequate 2.5 × 107 TNC/kg body weight.
To summarize, The results of outcome of the patients in the first MaxCell series [18] appear to
be at least comparable to those reported in the medical literature [19, 23–34] and in some
instances, superior to those reported for RCR CB products [18, 35–43, 50–59]. Though, there
are no published data indicating inferior outcomes with transplantation using MaxCell units
[8, 35–43, 50–59], such retrospective comparisons cannot be definitive. To analyze rigorously
the outcomes of MaxCell CBT in comparison with RCR units, matched-pair comparisons for
pediatric hematologic malignancies and thalassemia have shown significant improvements in
overall survival, disease-free survival, transplanted-related mortality, and platelet engraftment
for MaxCell CB products [35–38]. Moreover, when MaxCell CB products are coupled with
direct infusion, significantly improved overall survival, disease-free survival, transplanted-
related mortality, neutrophil, and platelet engraftment, higher limited cGvHD but lower
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extensive cGvHD have been reported and subsequently confirmed in matched-pair compari-
sons. In conclusion, CB transplants using products processed by MaxCell CB processing
technologies provide clinical outcome results that appear superior to results reported with the
use of 1st Gen RCR units. When combined with bedside thaw techniques in most situations,
further improvements can be expected [56–59].
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